Hi: This is heart breaking indeed. So, the bad news is that cataracts have begun to form, especially in one eye. The good news is that your horse still has sight out of one good eye and some sight out of the eye with the cataract. Research on Can-C reports that application of the Can-C eye drops as directed results in about 95% improvement in the subjects that were studied. Subjects have been dogs and humans – not horses – but researchers concluded that the Can-C helps reverse cataracts in all mammals including horses in, again, 95% of the cases. So, it is certainly worth a try, especially to insure that the good eye remains clear of a cataract.
Oral curcumin administration has been found to inhibit the development of chemically-induced cancer in animal models of oral (58, 59) , stomach (60, 61) , liver (62) , and colon (63-65) cancer. Apc Min/+ mice have a mutation in the Apc (adenomatous polyposis coli) gene similar to that in humans with familial adenomatous polyposis , a genetic condition characterized by the development of numerous colorectal adenomas ( polyps ) and a high risk for colorectal cancer . Oral curcumin administration has been found to inhibit the development of intestinal adenomas in Apc Min/+ mice (66, 67) . Despite promising results in animal studies, there is presently little evidence that high intakes of curcumin or turmeric are associated with decreased cancer risk in humans. A 30-day phase II clinical trial in 40 smokers with at least eight rectal aberrant crypt foci (ACF; precancerous lesions) found that the number of ACF was significantly lower with a daily supplementation with 4 g/day of curcumin compared to 2 g/day (68) . Several controlled clinical trials in humans designed to evaluate the effect of oral curcumin supplementation on precancerous colorectal lesions, such as adenomas, are under way (69) .
Acute gout attacks can be managed with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids (intra-articular injection or systemic). All three agents are appropriate first-line therapy for acute gout. Therapy should be initiated within 24 hours of onset. The drug selection is dictated by the patient's tolerance of those medications and the presence of any comorbid diseases that contraindicates the use of a specific drug. For patients with severe or refractory gout attacks, practitioners can try combining agents. If all of these medications are contraindicated in a patient, narcotics may be used short term to relieve pain until the acute attack has resolved. Long-term use of narcotics should be avoided.